In premenopausal node-positive, receptor-positive breast cancer, adding goserelin to CAF provided no overall advantage.
In plain wordsIn premenopausal node-positive, receptor-positive breast cancer, goserelin after CAF provided no overall advantage compared with CAF alone.
- Peptide
- Goserelin
- Outcome
- Direction not reportedOverall advantage of goserelin addition
- Study
n: not reported in source
- Comparator
- CAF chemotherapy alone
- Outcome group
- Cancer Survival · Cancer
- Studied dose
- Dose not stated · 5 yearsAs given in this study (human).
Source sentences
There was no overall advantage for addition of goserelin to CAF.
2 context sentences(design, population, supporting numbers)
Premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer (1,503 eligible patients) were randomly assigned to six cycles of cyclophosphamide, doxorubicin, and fluorouracil (CAF), CAF followed by 5 years of monthly goserelin (CAF-Z),
The primary end points were time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) for CAF-Z versus CAF, and CAF-ZT versus CAF-Z.